Australian OINDP specialist CDMO Ab Initio announced that the Therapeutic Goods administration of Australia (TGA) has granted the company a license to manufacture finished inhalation products and nasal sprays, in addition to other dosage forms. Ab Initio says that the license allows it to offer services including manufacturing of finished products for clinical trials, … [Read more...] about Ab Initio Pharma now able to manufacture OINDPs for clinical trials
News
Honeywell begins large-scale production of medical grade Solstice Air HFO-1234ze MDI propellant
Honeywell has begun large scale manufacturing of Solstice Air HFO-1234ze(E), a low global-warming-potential (GWP) MDI propellant, at a facility located in Baton Rouge, LA, USA, the company said. In February 2022, AstraZeneca announced that it would reformulate Breztri budesonide/ glycopyrronium/ formoterol fumarate using Solstice Air as part of a partnership … [Read more...] about Honeywell begins large-scale production of medical grade Solstice Air HFO-1234ze MDI propellant
Intravacc gets funding for intranasal gonorrhea and betacoronavirus vaccines
Dutch intranasal vaccine developer and CDMO Intravacc said that it has received an award of up to $14.6 million from the US National Institute of Allergy and Infectious Diseases (NIAID) to support development of an intranasal vaccine against gonorrhea and another award of up to $4.8 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to support … [Read more...] about Intravacc gets funding for intranasal gonorrhea and betacoronavirus vaccines
Synairgen announces top-line data from Phase 2 ACTIV-2 trial of SNG001 nebulized interferon-beta-1a for mild-to-moderate COVID-19
Synairgen has announced that the Phase 2 ACTIV-2 trial of SNG001 inhaled interferon-beta-1a in non-hospitalized COVID-19 patients failed to show a statistically significant reduction in hospitalization, viral load, safety, or resolution of symptoms compared to placebo, but the study did demonstrate a relative reduction of 86% in hospitalization. Over the course of the … [Read more...] about Synairgen announces top-line data from Phase 2 ACTIV-2 trial of SNG001 nebulized interferon-beta-1a for mild-to-moderate COVID-19
InCarda Therapeutics names Robert Lisicki as CEO
Inhaled flecanide developer InCarda Therapeutics has named former Arena Pharmaceuticals executive Robert Lisicki as CEO, succeeding Grace Colón who the company says "intends to pursue other leadership opportunities within the life science space" but will continue to consult for InCarda. In addition to having served as Chief Commercial Officer at Arena, Lisicki … [Read more...] about InCarda Therapeutics names Robert Lisicki as CEO
Pfizer completes acquisition of Biohaven and its zagevepant nasal spray
Pfizer has completed its acquisition of Biohaven Pharmaceutical, including Biohaven's intranasal zavegepant (BHV-3500) calcitonin gene-related peptide (CGRP) receptor antagonist, the company said. Pfizer announced that it had acquired the ex-US rights to zavegepant and Nurtec ODT rimegepant from Biohaven January 2022. By the time that the FDA accepted Biohaven's NDA … [Read more...] about Pfizer completes acquisition of Biohaven and its zagevepant nasal spray
HCmed Innovations and AeroRx Therapeutics partner on nebulized LABA/LAMA for COPD
Startup inhaled drug developer AeroRx Therapeutics and nebulizer maker HCmed Innovations have announced that they will partner on development of a nebulized LABA/LAMA inhalation solution for the treatment of COPD. AeroRx is a spinoff of iPharma Labs, which was acquired by Kindeva Drug Delivery earlier this year. In March 2022, HCmed announced that it was partnering … [Read more...] about HCmed Innovations and AeroRx Therapeutics partner on nebulized LABA/LAMA for COPD
OINDP specialists to gather in Edinburgh and online for DDL 2022
Registration is open for DDL 2022, which will be the first in-person Drug Delivery to the Lungs meeting since the beginning of the COVID-19 pandemic. The meeting will take place December 7-9 and is expected to attract hundreds of delegates to the Edinburgh International Conference Centre (EICC), with additional delegates able to access the programming online in real … [Read more...] about OINDP specialists to gather in Edinburgh and online for DDL 2022
Odyssey Health says Phase 1 results for PRV-002 intranasal therapy for concussion support advancing the nasal powder to Phase 2
Odyssey Health announced that it has completed its Phase 1 study of PRV-002, a novel intranasal synthetic neurosteroid powder formulation that the company is developing for the treatment of concussion, and said that the results support advancing PRV-002 into Phase 2 trials. Odyssey acquired PRV-002 from Prevacus in January 2021. The company recently announced that the … [Read more...] about Odyssey Health says Phase 1 results for PRV-002 intranasal therapy for concussion support advancing the nasal powder to Phase 2
Transpire Bio contracts with Recipharm for development of two more inhaled drugs
After announcing a deal with Recipharm for development of two inhaled drugs (TRB-1 and TRB-2) earlier this year, Transpire Bio says that it has signed an agreement with the CDMO for development of an additional two inhaled products. Under the new agreement, Recipharm will provide development services for Transpire's TRB-3 and TRB-4 inhaled therapeutics for the … [Read more...] about Transpire Bio contracts with Recipharm for development of two more inhaled drugs